Followers | 374 |
Posts | 16919 |
Boards Moderated | 4 |
Alias Born | 03/07/2014 |
Friday, August 01, 2014 7:42:16 PM
There is little or no "trial" spending going on, as the total "R&D" expense line is about $5K a month. Look at past filings when they were running actual "trials", as in FDA type trials. That R&D line was many multiples of that. Just in the same period 2013, it was $172K versus this paltry $15K.
They can't "hide" or "wash" supposed "trial spending" under some mysterious part of their financial statements or hidden place in the 10-Q? That's not how it works.
There's some good web sites and good books at any library on reading and understanding things like basic "financials" (commonly known as a set of financials or financial statements for a business)- typically a balance sheet, an income statement, a statement of cash flows and probably stockholder's equity. There's a few variations, but those are the jest of a typical set of "financials". That's the "snap shot" of pretty much everything key in terms of money coming in, money going out, expenses, income/revenue, interest paid, short and long term debt, etc. In this 10-Q filing, it's pretty much pages 4, 5, 6 and 7. Read those.
FEATURED Element79 Gold To Provide Summary and Update on Active Exploration Program, Community Relations at RMEC on June 4 • May 30, 2024 1:18 PM
Branded Legacy Secures Exclusive Extraction Partnership with One of the World's Largest Kava Distributors and Producers • BLEG • May 30, 2024 8:30 AM
ECGI Holdings, Inc. Announces $2 Million Debt-to-Equity Conversion • ECGI • May 30, 2024 8:30 AM
North Bay Resources Reports Assays up to >25% Mg, 0.1% Ni, 0.1% Cu, 0.01% Co, 0.3 ppm Pt at Tulameen Platinum Project, British Columbia • NBRI • May 29, 2024 9:03 AM
One World Products, Inc. Issues Shareholder Update • OWPC • May 29, 2024 8:20 AM
Green Leaf Innovations, Inc. Engages Olayinka Oyebola & Co for Two-Year Audit • GRLF • May 28, 2024 8:30 AM